BEST1-Related Dominant Retinopathy

Mendelian MONDO:0700238 Pathograph 11 Show in embeddings browser Ophthalmological Disease Retinal Dystrophy Inherited retinal dystrophy

BEST1-related dominant retinopathy encompasses inherited macular dystrophies caused by heterozygous pathogenic variants in BEST1, which encodes bestrophin-1, a calcium-activated chloride channel (CaCC) in the basolateral membrane of the retinal pigment epithelium (RPE). The prototypic and most prevalent form is Best vitelliform macular dystrophy (BVMD/Best disease), characterized by progressive accumulation of lipofuscin-rich vitelliform ("egg-yolk") deposits in the subretinal macular space, a pathognomonic reduction of the electrooculogram (EOG) light-rise, and slowly progressive central visual impairment. Dominant pathogenic BEST1 variants act through loss-of-function, dominant-negative, or gain-of-function mechanisms; with over 250 known pathogenic variants, the disorder shows marked variable expressivity and incomplete penetrance. No approved disease-modifying treatments exist; the first interventional gene therapy trial (BIRD-1/OPGx-BEST1, NCT07185256) began enrolling in 2025.

Ask OpenScientist

Ask a research question about BEST1-Related Dominant Retinopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal dominant HP:0000006

BVMD follows autosomal dominant inheritance with incomplete penetrance and marked variable expressivity. Asymptomatic carriers with pathogenic BEST1 variants may show only reduced EOG without visible macular lesions. Intrafamilial phenotypic diversity is pronounced, with some heterozygous carriers showing no visible fundus changes.

Autosomal dominant inheritance

Show evidence (4 references)

DOI:10.1002/mgg3.2095 SUPPORT Human Clinical

"patients carrying a pathogenic heterozygous variant of BEST1 to develop obvious intrafamilial phenotypic diversity"

Family-based clinical genetic study demonstrates marked intrafamilial phenotypic diversity characteristic of dominant BEST1 disease with variable expressivity.

DOI:10.1177/2515841421997191 SUPPORT Human Clinical

"over 250 individual pathological mutations have been identified in the BEST1 gene, with many reported to have various clinical expressivity and incomplete penetrance"

Documents incomplete penetrance and variable clinical expressivity as characteristic features of dominant BEST1 inheritance.

PMID:20301346 SUPPORT Human Clinical

"BVMD, AVMD, and ADVIRC are inherited in an autosomal dominant (AD) manner."

GeneReviews explicitly confirms autosomal dominant inheritance as the mode for all three dominant BEST1 bestrophinopathy phenotypes.

+ 1 more reference

⚙

Pathophysiology

BEST1 Calcium-Activated Chloride Channel Dysfunction

Heterozygous pathogenic BEST1 variants produce mutant bestrophin-1 subunits that co-assemble with wild-type subunits in the homopentameric CaCC complex in the RPE basolateral membrane. The large majority of dominant BEST1 pathogenic variants cause loss-of-function (LOF) or dominant-negative (DN) impairment of calcium-activated chloride conductance; a minority cause toxic gain-of-function (GOF) with excess channel activity. The resulting abnormal chloride transport disrupts RPE transepithelial ion flux and calcium homeostasis.

retinal pigment epithelial cell CL:0002586

BEST1 hgnc:12703

chloride transport GO:0006821 ↓ DECREASED

Downstream

RPE Dysfunction and Impaired Phagocytosis Impaired CaCC activity disrupts calcium signaling, transepithelial fluid transport, and phagocytic uptake of shed photoreceptor outer segments in the RPE.

Show evidence (4 references)

DOI:10.4103/sjopt.sjopt_175_23 SUPPORT In Vitro

"most BEST1 pathogenic variants have been shown to cause either loss of function (LOF) of the protein or a dominant-negative (DN) effect, with a smaller subset causing a toxic gain of function (GOF)"

Review of bestrophinopathy gene therapy preclinical studies characterizes the three molecular mechanisms (LOF, DN, GOF) by which dominant BEST1 variants impair bestrophin-1 channel function, with implications for therapeutic strategy.

DOI:10.1177/2515841421997191 SUPPORT In Vitro

"bestrophin1 (BEST1), a protein thought to act as a Ca2+-activated Cl- channel in the retinal pigment epithelium (RPE) of the eye"

Establishes bestrophin-1 as the calcium-activated chloride channel in RPE whose dysfunction underlies bestrophinopathies.

DOI:10.3390/ijms26199421 SUPPORT In Vitro

"BEST1 gene encodes a transmembrane protein in the retinal pigment epithelium (RPE) in the eye, that functions as a calcium-dependent chloride channel (CaCC)"

Gene therapy strategy review confirms bestrophin-1 CaCC identity and RPE localization as the basis of BEST1-related retinopathy mechanisms.

+ 1 more reference

RPE Dysfunction and Impaired Phagocytosis

Bestrophin-1 CaCC dysfunction impairs multiple interdependent RPE functions: calcium homeostasis, transepithelial fluid transport, and phagocytic uptake of daily-shed photoreceptor outer segments (POS). Failure of RPE phagocytosis allows undigested POS to accumulate in the subretinal space. The pathognomonic reduction of the EOG Arden ratio (light-rise) is the electrophysiological readout of this RPE-level dysfunction, present even in asymptomatic BEST1 carriers.

retinal pigment epithelial cell CL:0002586

phagocytosis GO:0006909 ↓ DECREASED retina homeostasis GO:0001895 ↓ DECREASED

Downstream

Vitelliform Material Accumulation Impaired RPE phagocytosis and fluid transport lead to subretinal accumulation of lipofuscin-rich unphagocytosed outer-segment material, forming the characteristic vitelliform deposit.

Show evidence (3 references)

DOI:10.3390/ijms23137432 SUPPORT In Vitro

"mutations in this gene induce functional problems in the RPE cell layer with an accumulation of lipofucsin that evolves into cell death and loss of sight"

iPSC-RPE model of BVMD demonstrates that BEST1 mutations cause RPE dysfunction leading to lipofuscin accumulation and eventual cell death.

DOI:10.1007/s10633-026-10093-y SUPPORT Human Clinical

"The light-rise of the electro-oculogram (EOG) is used as a clinical marker for a collection of disorders known as the 'bestrophinopathies.'"

The reduced EOG light-rise is the pathognomonic RPE electrophysiological signature of bestrophinopathy, reflecting the underlying bestrophin-1 CaCC dysfunction in RPE.

DOI:10.1111/aos.14958 SUPPORT Human Clinical

"The Arden ratio was significantly lower in ARB patients and in eyes with stage 5 of BVMD"

Clinical cohort study confirms reduced EOG Arden ratio across BVMD stages, with the most severe reduction in end-stage (atrophic) disease.

Vitelliform Material Accumulation

Impaired RPE phagocytosis of shed photoreceptor outer segments and disrupted subretinal fluid homeostasis lead to progressive subretinal accumulation of lipofuscin-rich, hyperautofluorescent material beneath the macula. Quantitative autofluorescence studies indicate that lipofuscin accumulation is not a primary consequence of the genetic defect, but reflects secondary failure of RPE-photoreceptor apposition and POS clearance. The hallmark "egg-yolk" vitelliform lesion evolves through five classical stages over years to decades: previtelliform, vitelliform, pseudohypopyon, vitelliruptive ("scrambled-egg"), and atrophic/fibroatrophic.

retinal pigment epithelial cell CL:0002586

photoreceptor cell maintenance GO:0045494 ↓ DECREASED

macula lutea UBERON:0000053 fovea centralis UBERON:0001786

Downstream

Progressive Photoreceptor Damage and Vision Loss Chronic subretinal lipofuscin-rich deposit disrupts photoreceptor-RPE apposition and causes progressive structural cone photoreceptor damage, ONL thinning, and ellipsoid zone disruption.

Show evidence (1 reference)

DOI:10.1177/11206721231166434 SUPPORT Human Clinical

"lipofuscin accumulation, the hallmark of BVMD, is unlikely to be a primary effect of the genetic defect. It could be due to a lack of apposition between photoreceptors and retinal pigment epithelium in the macula with subsequent accumulation of shed outer segments over time"

Quantitative FAF imaging review establishes that vitelliform material accumulates secondary to impaired RPE-photoreceptor apposition and POS phagocytosis, not as a direct primary effect of BEST1 dysfunction.

Progressive Photoreceptor Damage and Vision Loss

The subretinal vitelliform deposit progressively disrupts photoreceptor-RPE apposition and causes structural damage to the cone-dominated macular photoreceptors. OCT and adaptive optics imaging demonstrate progressive disruption of the cone mosaic, followed by outer nuclear layer (ONL) thinning and ellipsoid zone (EZ) disruption. In late stages, choroidal neovascularization (CNV) can develop beneath the damaged RPE, causing exudative complications and acute vision loss on a background of slow chronic progression.

cone photoreceptor cell CL:0000573

photoreceptor cell maintenance GO:0045494 ↓ DECREASED visual perception GO:0007601 ↓ DECREASED

macula lutea UBERON:0000053

Show evidence (2 references)

DOI:10.1177/11206721231166434 SUPPORT Human Clinical

"vitelliform lesions are characterized by progressive changes in the cone mosaic corresponding to a thinning of the outer nuclear layer and then disruption of the ellipsoid zone, which are associated with a decreased sensitivity and visual acuity"

OCT and adaptive optics imaging directly demonstrate progressive cone mosaic disruption and ONL thinning as the structural basis of visual loss in BVMD.

DOI:10.1177/11206721231166434 SUPPORT Human Clinical

"OCT Angiography proved a greater prevalence of macular neovascularization, the majority of which are non-exudative and develop in late disease stages"

OCT angiography demonstrates that macular neovascularization is prevalent in late-stage BVMD, with most cases non-exudative; exudative CNV represents a serious complication requiring anti-VEGF treatment.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Eye 3

Abnormal electrooculogram VERY_FREQUENT Abnormal visual electrophysiology HP:0030453

Show evidence (2 references)

DOI:10.1007/s10633-026-10093-y SUPPORT Human Clinical

"The light-rise of the electro-oculogram (EOG) is used as a clinical marker for a collection of disorders known as the 'bestrophinopathies.'"

The EOG light-rise reduction is the pathognomonic functional RPE marker used clinically to diagnose and classify bestrophinopathies.

DOI:10.1111/aos.14958 SUPPORT Human Clinical

"The Arden ratio was significantly lower in ARB patients and in eyes with stage 5 of BVMD"

Clinical cohort data confirm that reduced Arden ratio (EOG light-rise) is present across BVMD stages, with severity correlating with disease stage.

Reduced visual acuity FREQUENT Reduced visual acuity HP:0007663

Course: PROGRESSIVE

Show evidence (3 references)

DOI:10.1177/11206721231166434 SUPPORT Human Clinical

OCT studies demonstrate that progressive structural cone/ONL damage directly correlates with reduced visual acuity in BVMD.

DOI:10.1111/aos.14958 SUPPORT Human Clinical

"The genotype does not always predict the phenotype in patients with BVMD and ARB"

Clinical cohort study confirms that disease course is not strictly determined by genotype, consistent with the variable expressivity and often slowly progressive character of BVMD with relatively preserved visual function in many patients over 5 years of follow-up.

PMID:20301346 SUPPORT Human Clinical

"Slow visual deterioration is the usual course."

GeneReviews confirms slowly progressive visual impairment as the typical clinical trajectory of bestrophinopathies, consistent with often-preserved VA in early stages and the long window of opportunity for intervention.

Macular atrophy OCCASIONAL Macular atrophy HP:0007401

Show evidence (2 references)

DOI:10.1111/aos.14958 SUPPORT Human Clinical

"categorization of 52 eyes as Best vitelliform macular dystrophy (BVMD) with stages 1 to 5"

Clinical staging in a 62-eye cohort demonstrates the full BVMD progression from stage 1 (previtelliform) through stage 5 (atrophic/cicatricial), confirming macular atrophy as a recognized end-stage phenotype.

DOI:10.1111/aos.14958 SUPPORT Human Clinical

"the atrophic stage of BVMD"

The same cohort study identifies the atrophic stage of BVMD as the disease end-stage with the worst visual function and EOG results, directly anchoring macular atrophy as the terminal BVMD phenotype.

Other 3

Vitelliform macular lesion VERY_FREQUENT Vitelliform-like macular lesions HP:0007677

Show evidence (2 references)

DOI:10.1177/11206721231166434 SUPPORT Human Clinical

"Best Vitelliform Macular Dystrophy (BVMD) is a dominantly inherited retinal disease caused by dominant variants in the BEST1 gene"

Multimodal imaging review establishes the vitelliform macular lesion as the defining hallmark of BVMD, caused by dominant BEST1 variants.

PMID:20301346 SUPPORT Human Clinical

"The four recognized phenotypes are the three autosomal dominant disorders: Best vitelliform macular dystrophy (BVMD), BEST1 adult-onset vitelliform macular dystrophy (AVMD), and autosomal dominant vitreoretinochoroidopathy (ADVIRC); and autosomal recessive bestrophinopathy (ARB)."

GeneReviews identifies BVMD (with its vitelliform macular lesion) as the prototypic autosomal-dominant BEST1 phenotype, anchoring the cardinal diagnostic feature in the authoritative clinical reference.

Metamorphopsia OCCASIONAL Metamorphopsia HP:0012508

Show evidence (1 reference)

PMID:36281445 SUPPORT Human Clinical

"A 12-year-old boy complaining of metamorphopsia presented with bilateral yellowish subfoveal deposits, suggestive of BVMD, which was confirmed by fundus autofluorescence and electrooculography"

Case report of BVMD in which metamorphopsia was the presenting symptom, directly documenting metamorphopsia arising from the subfoveal vitelliform lesion.

Choroidal neovascularization OCCASIONAL Choroidal neovascularization HP:0011506

Show evidence (2 references)

DOI:10.1177/11206721231166434 SUPPORT Human Clinical

"OCT Angiography proved a greater prevalence of macular neovascularization, the majority of which are non-exudative and develop in late disease stages"

OCT angiography studies demonstrate macular neovascularization as a frequent late-stage BVMD finding, with the majority non-exudative.

PMID:20301346 SUPPORT Human Clinical

"Choroidal neovascularization can occur in rare cases."

GeneReviews confirms choroidal neovascularization as a recognized, though uncommon, late complication of bestrophinopathies, warranting annual ophthalmologic surveillance for its detection.

🧬

Genetic Associations

BEST1 heterozygous pathogenic variant (Causative)

Gene: BEST1 hgnc:12703

Show evidence (3 references)

DOI:10.1177/2515841421997191 SUPPORT Human Clinical

"over 250 individual pathological mutations have been identified in the BEST1 gene, with many reported to have various clinical expressivity and incomplete penetrance"

Establishes the genetic landscape: over 250 BEST1 pathogenic variants underlie the bestrophinopathies, with variable expressivity and incomplete penetrance characterizing the dominant forms.

DOI:10.1002/mgg3.2095 SUPPORT Human Clinical

"A total of 9 variants on the BEST1 gene were identified, containing 7 missense variants, 1 nonsense variant, and 1 frameshift variant"

Family-based genetic study of bestrophinopathies demonstrates the variant type distribution: predominantly missense, with minority frameshift/nonsense variants.

DOI:10.4103/sjopt.sjopt_175_23 SUPPORT In Vitro

"most BEST1 pathogenic variants have been shown to cause either loss of function (LOF) of the protein or a dominant-negative (DN) effect, with a smaller subset causing a toxic gain of function (GOF)"

Categorizes BEST1 variant molecular mechanisms with important therapeutic implications: GOF variants require combined gene silencing + augmentation versus augmentation alone for LOF/DN.

💊

Medical Actions

Anti-VEGF Therapy for Choroidal Neovascularization

Action: Pharmacotherapy NCIT:C15986

Agent: angiogenesis inhibitor (anti-VEGF) NCIT:C1742

Intravitreal anti-VEGF agents (e.g., bevacizumab, ranibizumab) are the current standard of care for exudative choroidal neovascularization complicating late-stage BVMD. No approved disease-modifying therapy exists for the underlying bestrophinopathy.

Target Phenotypes: Choroidal neovascularization HP:0011506

Show evidence (2 references)

DOI:10.1177/2515841421997191 SUPPORT Human Clinical

"no current clinical treatments available for patients with bestrophinopathies"

Confirms that no approved disease-modifying treatment exists for bestrophinopathies; anti-VEGF for CNV is the only currently available targeted intervention.

PMID:36281445 SUPPORT Human Clinical

"suggest a favorable long-term prognosis for intravitreal anti-VEGF injections in eyes with BVMD presenting with early complicating MNVs"

Case report with 2-year follow-up documents a favorable response to intravitreal anti-VEGF (ranibizumab) for macular neovascularization complicating BVMD, supporting anti-VEGF as standard of care for the exudative/neovascular complication.

OPGx-BEST1 Gene Augmentation Therapy (BIRD-1 Trial)

Action: gene therapy MAXO:0001001

OPGx-BEST1 (Opus Genetics) is a recombinant AAV vector delivering a codon-optimized full-length human BEST1 cDNA under an RPE-specific VMD2 promoter, administered by subretinal injection. The Phase 1b/2a BIRD-1 trial (NCT07185256) opened for enrollment in 2025, exploring two doses (1.5E9 and 4.5E9 vg/eye) with 5-year follow-up. Both LOF and DN mutations are potentially amenable to gene augmentation alone; GOF variants would require concurrent gene silencing.

Target Phenotypes: Vitelliform macular lesion HP:0007677

Show evidence (3 references)

clinicaltrials:NCT07185256 SUPPORT Human Clinical

"Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the treatment eye), for 5 years post-injection, in participants with BVMD or ARB"

The first interventional gene therapy trial for bestrophinopathies is actively recruiting; OPGx-BEST1 subretinal gene delivery targets both BVMD (dominant) and ARB (recessive) patients.

DOI:10.3390/ijms26199421 SUPPORT In Vitro

"gene augmentation may be effective for a subset of bestrophinopathies, others require allele-specific silencing or correction of the disease-causing variant"

Establishes that gene augmentation (the OPGx-BEST1 approach) is appropriate for LOF/DN variants but that GOF variants require additional silencing strategies, informing patient eligibility and future trial design.

DOI:10.4103/sjopt.sjopt_175_23 SUPPORT In Vitro

"individuals harboring GOF variants would require a combination of gene silencing and gene augmentation, which has been shown to be effective in RPE cells derived from patients with Best disease"

Demonstrates proof-of-concept for combined silencing + augmentation for GOF BEST1 variants in iPSC-RPE, supporting the therapeutic rationale for BEST1 gene therapy.

Annual Ophthalmologic Surveillance

Action: eye examination MAXO:0001155

Annual ophthalmologic examination including best-corrected visual acuity, visual fields, and spectral-domain OCT to monitor fundus lesion progression and detect the development of choroidal neovascularization. In children with BVMD, annual ophthalmologic examinations also help prevent amblyopia development.

Target Phenotypes: Choroidal neovascularization HP:0011506 Reduced visual acuity HP:0007663

Show evidence (1 reference)

PMID:20301346 SUPPORT Human Clinical

"Annual ophthalmologic examination (including best corrected visual acuity, visual fields, and spectral domain optical coherence tomography) to monitor progression of fundus lesions and to evaluate for coincidental development of CNV; in childhood, perform annual ophthalmologic examinations to..."

GeneReviews recommends annual ophthalmologic surveillance including BCVA, visual fields, and SD-OCT as standard of care for bestrophinopathies, specifically to monitor disease progression and detect CNV.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Genetic counseling is recommended for all affected individuals and their families, particularly given the autosomal dominant inheritance with incomplete penetrance and marked variable expressivity, and the availability of cascade genetic testing for at-risk family members.

Show evidence (3 references)

DOI:10.1177/2515841421997191 SUPPORT Human Clinical

"over 250 individual pathological mutations have been identified in the BEST1 gene, with many reported to have various clinical expressivity and incomplete penetrance"

The broad genetic heterogeneity and variable penetrance/expressivity of dominant BEST1 disease make genetic counseling essential for accurate risk assessment and family planning guidance.

PMID:20301346 SUPPORT Human Clinical

"Once the BEST1 pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for a bestrophinopathy are possible."

GeneReviews confirms that once a causative BEST1 variant is identified, prenatal diagnostic testing and preimplantation genetic testing are available options, which should be communicated during genetic counseling.

PMID:20301346 SUPPORT Human Clinical

"Evaluation of relatives at risk: It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from prompt ophthalmologic evaluation and routine follow up."

GeneReviews recommends cascade genetic testing for at-risk relatives, because asymptomatic carriers may have subclinical RPE dysfunction detectable only by EOG or molecular testing.

{ }

Source YAML

click to show

name: BEST1-Related Dominant Retinopathy
creation_date: "2026-06-23T00:00:00Z"
category: Mendelian
description: >-
  BEST1-related dominant retinopathy encompasses inherited macular dystrophies
  caused by heterozygous pathogenic variants in BEST1, which encodes bestrophin-1,
  a calcium-activated chloride channel (CaCC) in the basolateral membrane of the
  retinal pigment epithelium (RPE). The prototypic and most prevalent form is
  Best vitelliform macular dystrophy (BVMD/Best disease), characterized by
  progressive accumulation of lipofuscin-rich vitelliform ("egg-yolk") deposits
  in the subretinal macular space, a pathognomonic reduction of the
  electrooculogram (EOG) light-rise, and slowly progressive central visual
  impairment. Dominant pathogenic BEST1 variants act through loss-of-function,
  dominant-negative, or gain-of-function mechanisms; with over 250 known
  pathogenic variants, the disorder shows marked variable expressivity and
  incomplete penetrance. No approved disease-modifying treatments exist; the
  first interventional gene therapy trial (BIRD-1/OPGx-BEST1, NCT07185256)
  began enrolling in 2025.
disease_term:
  preferred_term: BEST1-related dominant retinopathy
  term:
    id: MONDO:0700238
    label: BEST1-related dominant retinopathy
synonyms:
- Best vitelliform macular dystrophy
- BVMD
- Best disease
- vitelliform macular dystrophy 2
- bestrophinopathy
- VMD2
parents:
- Ophthalmological Disease
- Retinal Dystrophy
- Inherited retinal dystrophy
notes: >-
  MONDO:0700238 captures autosomal-dominant BEST1 retinopathies only. The
  broader bestrophinopathy spectrum (including autosomal recessive
  bestrophinopathy, ADVIRC, MRCS, and BEST1-associated RP) is covered in
  BEST1_Bestrophinopathies.yaml (MONDO:0000390). Adult-onset foveomacular
  vitelliform dystrophy (AVMD) includes BEST1-related cases as a gene-defined
  subtype in Adult_Onset_Foveomacular_Vitelliform_Dystrophy.yaml
  (MONDO:0011979). Autosomal recessive bestrophinopathy (ARB; OMIM 611809;
  MONDO:0012733) requires biallelic BEST1 mutations and is not captured here.
pathophysiology:
- name: BEST1 Calcium-Activated Chloride Channel Dysfunction
  description: >-
    Heterozygous pathogenic BEST1 variants produce mutant bestrophin-1 subunits
    that co-assemble with wild-type subunits in the homopentameric CaCC complex
    in the RPE basolateral membrane. The large majority of dominant BEST1
    pathogenic variants cause loss-of-function (LOF) or dominant-negative (DN)
    impairment of calcium-activated chloride conductance; a minority cause toxic
    gain-of-function (GOF) with excess channel activity. The resulting abnormal
    chloride transport disrupts RPE transepithelial ion flux and calcium
    homeostasis.
  genes:
  - preferred_term: BEST1
    term:
      id: hgnc:12703
      label: BEST1
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: chloride transport
    term:
      id: GO:0006821
      label: chloride transport
    modifier: DECREASED
  evidence:
  - reference: DOI:10.4103/sjopt.sjopt_175_23
    reference_title: "Gene therapy in bestrophinopathies: Insights from preclinical studies in preparation for clinical trials"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "most BEST1 pathogenic variants have been shown to cause either loss of function (LOF) of the protein or a dominant-negative (DN) effect, with a smaller subset causing a toxic gain of function (GOF)"
    explanation: >-
      Review of bestrophinopathy gene therapy preclinical studies characterizes
      the three molecular mechanisms (LOF, DN, GOF) by which dominant BEST1
      variants impair bestrophin-1 channel function, with implications for
      therapeutic strategy.
  - reference: DOI:10.1177/2515841421997191
    reference_title: "Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "bestrophin1 (BEST1), a protein thought to act as a Ca2+-activated Cl- channel in the retinal pigment epithelium (RPE) of the eye"
    explanation: >-
      Establishes bestrophin-1 as the calcium-activated chloride channel in RPE
      whose dysfunction underlies bestrophinopathies.
  - reference: DOI:10.3390/ijms26199421
    reference_title: "Gene Therapy Strategies for the Treatment of Bestrophinopathies"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "BEST1 gene encodes a transmembrane protein in the retinal pigment epithelium (RPE) in the eye, that functions as a calcium-dependent chloride channel (CaCC)"
    explanation: >-
      Gene therapy strategy review confirms bestrophin-1 CaCC identity and RPE
      localization as the basis of BEST1-related retinopathy mechanisms.
  - reference: DOI:10.3390/ijms23137432
    reference_title: "Impaired Bestrophin Channel Activity in an iPSC-RPE Model of Best Vitelliform Macular Dystrophy (BVMD) from an Early Onset Patient Carrying the P77S Dominant Mutation"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "presents an increased chloride entrance, indicating that the p.Pro77Ser variant might be a gain-of-function mutation"
    explanation: >-
      iPSC-RPE model of BVMD demonstrates a GOF mechanism for the p.Pro77Ser
      dominant mutation: increased chloride conductance, establishing that
      dominant BEST1 mutations act through multiple distinct mechanisms.
  downstream:
  - target: RPE Dysfunction and Impaired Phagocytosis
    description: >-
      Impaired CaCC activity disrupts calcium signaling, transepithelial fluid
      transport, and phagocytic uptake of shed photoreceptor outer segments
      in the RPE.
    causal_link_type: DIRECT
- name: RPE Dysfunction and Impaired Phagocytosis
  description: >-
    Bestrophin-1 CaCC dysfunction impairs multiple interdependent RPE functions:
    calcium homeostasis, transepithelial fluid transport, and phagocytic uptake of
    daily-shed photoreceptor outer segments (POS). Failure of RPE phagocytosis
    allows undigested POS to accumulate in the subretinal space. The pathognomonic
    reduction of the EOG Arden ratio (light-rise) is the electrophysiological
    readout of this RPE-level dysfunction, present even in asymptomatic BEST1
    carriers.
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: phagocytosis
    term:
      id: GO:0006909
      label: phagocytosis
    modifier: DECREASED
  - preferred_term: retina homeostasis
    term:
      id: GO:0001895
      label: retina homeostasis
    modifier: DECREASED
  evidence:
  - reference: DOI:10.3390/ijms23137432
    reference_title: "Impaired Bestrophin Channel Activity in an iPSC-RPE Model of Best Vitelliform Macular Dystrophy (BVMD) from an Early Onset Patient Carrying the P77S Dominant Mutation"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "mutations in this gene induce functional problems in the RPE cell layer with an accumulation of lipofucsin that evolves into cell death and loss of sight"
    explanation: >-
      iPSC-RPE model of BVMD demonstrates that BEST1 mutations cause RPE
      dysfunction leading to lipofuscin accumulation and eventual cell death.
  - reference: DOI:10.1007/s10633-026-10093-y
    reference_title: "Review of the clinical electrooculogram - Part 2: the bestrophinopathies and modified protocols"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The light-rise of the electro-oculogram (EOG) is used as a clinical marker for a collection of disorders known as the 'bestrophinopathies.'"
    explanation: >-
      The reduced EOG light-rise is the pathognomonic RPE electrophysiological
      signature of bestrophinopathy, reflecting the underlying bestrophin-1
      CaCC dysfunction in RPE.
  - reference: DOI:10.1111/aos.14958
    reference_title: "Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Arden ratio was significantly lower in ARB patients and in eyes with stage 5 of BVMD"
    explanation: >-
      Clinical cohort study confirms reduced EOG Arden ratio across BVMD stages,
      with the most severe reduction in end-stage (atrophic) disease.
  downstream:
  - target: Vitelliform Material Accumulation
    description: >-
      Impaired RPE phagocytosis and fluid transport lead to subretinal
      accumulation of lipofuscin-rich unphagocytosed outer-segment material,
      forming the characteristic vitelliform deposit.
    causal_link_type: DIRECT
- name: Vitelliform Material Accumulation
  description: >-
    Impaired RPE phagocytosis of shed photoreceptor outer segments and disrupted
    subretinal fluid homeostasis lead to progressive subretinal accumulation of
    lipofuscin-rich, hyperautofluorescent material beneath the macula. Quantitative
    autofluorescence studies indicate that lipofuscin accumulation is not a primary
    consequence of the genetic defect, but reflects secondary failure of
    RPE-photoreceptor apposition and POS clearance. The hallmark "egg-yolk"
    vitelliform lesion evolves through five classical stages over years to decades:
    previtelliform, vitelliform, pseudohypopyon, vitelliruptive ("scrambled-egg"),
    and atrophic/fibroatrophic.
  locations:
  - preferred_term: macula lutea
    term:
      id: UBERON:0000053
      label: macula lutea
  - preferred_term: fovea centralis
    term:
      id: UBERON:0001786
      label: fovea centralis
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: photoreceptor cell maintenance
    term:
      id: GO:0045494
      label: photoreceptor cell maintenance
    modifier: DECREASED
  evidence:
  - reference: DOI:10.1177/11206721231166434
    reference_title: "Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lipofuscin accumulation, the hallmark of BVMD, is unlikely to be a primary effect of the genetic defect. It could be due to a lack of apposition between photoreceptors and retinal pigment epithelium in the macula with subsequent accumulation of shed outer segments over time"
    explanation: >-
      Quantitative FAF imaging review establishes that vitelliform material
      accumulates secondary to impaired RPE-photoreceptor apposition and POS
      phagocytosis, not as a direct primary effect of BEST1 dysfunction.
  downstream:
  - target: Progressive Photoreceptor Damage and Vision Loss
    description: >-
      Chronic subretinal lipofuscin-rich deposit disrupts photoreceptor-RPE
      apposition and causes progressive structural cone photoreceptor damage,
      ONL thinning, and ellipsoid zone disruption.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - subretinal lipofuscin-rich material disrupting photoreceptor-RPE apposition
- name: Progressive Photoreceptor Damage and Vision Loss
  description: >-
    The subretinal vitelliform deposit progressively disrupts photoreceptor-RPE
    apposition and causes structural damage to the cone-dominated macular
    photoreceptors. OCT and adaptive optics imaging demonstrate progressive
    disruption of the cone mosaic, followed by outer nuclear layer (ONL) thinning
    and ellipsoid zone (EZ) disruption. In late stages, choroidal
    neovascularization (CNV) can develop beneath the damaged RPE, causing
    exudative complications and acute vision loss on a background of slow chronic
    progression.
  locations:
  - preferred_term: macula lutea
    term:
      id: UBERON:0000053
      label: macula lutea
  cell_types:
  - preferred_term: cone photoreceptor cell
    term:
      id: CL:0000573
      label: retinal cone cell
  biological_processes:
  - preferred_term: photoreceptor cell maintenance
    term:
      id: GO:0045494
      label: photoreceptor cell maintenance
    modifier: DECREASED
  - preferred_term: visual perception
    term:
      id: GO:0007601
      label: visual perception
    modifier: DECREASED
  evidence:
  - reference: DOI:10.1177/11206721231166434
    reference_title: "Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "vitelliform lesions are characterized by progressive changes in the cone mosaic corresponding to a thinning of the outer nuclear layer and then disruption of the ellipsoid zone, which are associated with a decreased sensitivity and visual acuity"
    explanation: >-
      OCT and adaptive optics imaging directly demonstrate progressive cone
      mosaic disruption and ONL thinning as the structural basis of visual
      loss in BVMD.
  - reference: DOI:10.1177/11206721231166434
    reference_title: "Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "OCT Angiography proved a greater prevalence of macular neovascularization, the majority of which are non-exudative and develop in late disease stages"
    explanation: >-
      OCT angiography demonstrates that macular neovascularization is prevalent
      in late-stage BVMD, with most cases non-exudative; exudative CNV
      represents a serious complication requiring anti-VEGF treatment.
phenotypes:
- name: Vitelliform macular lesion
  category: Ophthalmological
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    The hallmark of BVMD: a bilateral, dome-shaped, yellow "egg-yolk" subfoveal
    lesion of vitelliform material visible on fundoscopy, confirmed by
    hyperautofluorescence on FAF imaging and subretinal hyperreflective material
    on OCT. Present in the classic vitelliform stage; may be absent or subtle in
    the previtelliform and atrophic stages.
  phenotype_term:
    preferred_term: Vitelliform macular lesion
    term:
      id: HP:0007677
      label: Vitelliform-like macular lesions
  evidence:
  - reference: DOI:10.1177/11206721231166434
    reference_title: "Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Best Vitelliform Macular Dystrophy (BVMD) is a dominantly inherited retinal disease caused by dominant variants in the BEST1 gene"
    explanation: >-
      Multimodal imaging review establishes the vitelliform macular lesion as
      the defining hallmark of BVMD, caused by dominant BEST1 variants.
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The four recognized phenotypes are the three autosomal dominant disorders: Best vitelliform macular dystrophy (BVMD), BEST1 adult-onset vitelliform macular dystrophy (AVMD), and autosomal dominant vitreoretinochoroidopathy (ADVIRC); and autosomal recessive bestrophinopathy (ARB)."
    explanation: >-
      GeneReviews identifies BVMD (with its vitelliform macular lesion) as the
      prototypic autosomal-dominant BEST1 phenotype, anchoring the cardinal
      diagnostic feature in the authoritative clinical reference.
- name: Abnormal electrooculogram
  category: Ophthalmological
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Reduced or absent EOG light-rise (Arden ratio typically below 1.5) is the
    pathognomonic electrophysiological feature of BVMD. It reflects underlying
    RPE dysfunction and can be present in asymptomatic BEST1 carriers before any
    visible macular change.
  phenotype_term:
    preferred_term: Abnormal electrooculogram
    term:
      id: HP:0030453
      label: Abnormal visual electrophysiology
  evidence:
  - reference: DOI:10.1007/s10633-026-10093-y
    reference_title: "Review of the clinical electrooculogram - Part 2: the bestrophinopathies and modified protocols"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The light-rise of the electro-oculogram (EOG) is used as a clinical marker for a collection of disorders known as the 'bestrophinopathies.'"
    explanation: >-
      The EOG light-rise reduction is the pathognomonic functional RPE marker
      used clinically to diagnose and classify bestrophinopathies.
  - reference: DOI:10.1111/aos.14958
    reference_title: "Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Arden ratio was significantly lower in ARB patients and in eyes with stage 5 of BVMD"
    explanation: >-
      Clinical cohort data confirm that reduced Arden ratio (EOG light-rise)
      is present across BVMD stages, with severity correlating with disease stage.
- name: Reduced visual acuity
  category: Ophthalmological
  frequency: FREQUENT
  description: >-
    Progressive central visual impairment that correlates with structural
    macular damage; visual function is often relatively preserved in early
    vitelliform stages despite prominent lesion appearance.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
    clinical_course: PROGRESSIVE
  evidence:
  - reference: DOI:10.1177/11206721231166434
    reference_title: "Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "vitelliform lesions are characterized by progressive changes in the cone mosaic corresponding to a thinning of the outer nuclear layer and then disruption of the ellipsoid zone, which are associated with a decreased sensitivity and visual acuity"
    explanation: >-
      OCT studies demonstrate that progressive structural cone/ONL damage
      directly correlates with reduced visual acuity in BVMD.
  - reference: DOI:10.1111/aos.14958
    reference_title: "Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The genotype does not always predict the phenotype in patients with BVMD and ARB"
    explanation: >-
      Clinical cohort study confirms that disease course is not strictly
      determined by genotype, consistent with the variable expressivity and
      often slowly progressive character of BVMD with relatively preserved
      visual function in many patients over 5 years of follow-up.
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Slow visual deterioration is the usual course."
    explanation: >-
      GeneReviews confirms slowly progressive visual impairment as the typical
      clinical trajectory of bestrophinopathies, consistent with often-preserved
      VA in early stages and the long window of opportunity for intervention.
- name: Metamorphopsia
  category: Ophthalmological
  frequency: OCCASIONAL
  description: Distortion of central vision from the subfoveal vitelliform macular lesion.
  phenotype_term:
    preferred_term: Metamorphopsia
    term:
      id: HP:0012508
      label: Metamorphopsia
  evidence:
  - reference: PMID:36281445
    reference_title: "Temporary Vitelliform Regression After Intravitreal Ranibizumab Injection for Macular Neovascularization Complicating Best Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 12-year-old boy complaining of metamorphopsia presented with bilateral yellowish subfoveal deposits, suggestive of BVMD, which was confirmed by fundus autofluorescence and electrooculography"
    explanation: >-
      Case report of BVMD in which metamorphopsia was the presenting symptom,
      directly documenting metamorphopsia arising from the subfoveal vitelliform
      lesion.
- name: Macular atrophy
  category: Ophthalmological
  frequency: OCCASIONAL
  description: >-
    End-stage finding with RPE and outer retinal atrophy in the macular region,
    developing as the vitelliform lesion progresses through vitelliruptive to
    atrophic stage.
  phenotype_term:
    preferred_term: Macular atrophy
    term:
      id: HP:0007401
      label: Macular atrophy
  evidence:
  - reference: DOI:10.1111/aos.14958
    reference_title: "Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "categorization of 52 eyes as Best vitelliform macular dystrophy (BVMD) with stages 1 to 5"
    explanation: >-
      Clinical staging in a 62-eye cohort demonstrates the full BVMD progression
      from stage 1 (previtelliform) through stage 5 (atrophic/cicatricial),
      confirming macular atrophy as a recognized end-stage phenotype.
  - reference: DOI:10.1111/aos.14958
    reference_title: "Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the atrophic stage of BVMD"
    explanation: >-
      The same cohort study identifies the atrophic stage of BVMD as the disease
      end-stage with the worst visual function and EOG results, directly anchoring
      macular atrophy as the terminal BVMD phenotype.
- name: Choroidal neovascularization
  category: Ophthalmological
  frequency: OCCASIONAL
  description: >-
    Macular choroidal neovascularization develops as a late complication of RPE
    damage and atrophy, causing exudative complications and acute vision loss.
    Most CNV in BVMD is non-exudative on OCT-A.
  phenotype_term:
    preferred_term: Choroidal neovascularization
    term:
      id: HP:0011506
      label: Choroidal neovascularization
  evidence:
  - reference: DOI:10.1177/11206721231166434
    reference_title: "Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "OCT Angiography proved a greater prevalence of macular neovascularization, the majority of which are non-exudative and develop in late disease stages"
    explanation: >-
      OCT angiography studies demonstrate macular neovascularization as a
      frequent late-stage BVMD finding, with the majority non-exudative.
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Choroidal neovascularization can occur in rare cases."
    explanation: >-
      GeneReviews confirms choroidal neovascularization as a recognized, though
      uncommon, late complication of bestrophinopathies, warranting annual
      ophthalmologic surveillance for its detection.
genetic:
- name: BEST1 heterozygous pathogenic variant
  gene_term:
    preferred_term: BEST1
    term:
      id: hgnc:12703
      label: BEST1
  association: Causative
  features: >-
    Dominant BEST1-related retinopathy is caused by heterozygous pathogenic
    variants in BEST1 (bestrophin-1, HGNC:12703). Over 250 pathogenic BEST1
    variants are known; the vast majority are missense mutations, with a minority
    nonsense, frameshift, or splice-site variants. Three molecular mechanisms
    operate: dominant-negative (DN, most common), loss-of-function (LOF), and
    gain-of-function (GOF, minority). Both LOF and DN mutations may respond to
    gene augmentation therapy, while GOF mutations require gene silencing plus
    augmentation.
  evidence:
  - reference: DOI:10.1177/2515841421997191
    reference_title: "Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "over 250 individual pathological mutations have been identified in the BEST1 gene, with many reported to have various clinical expressivity and incomplete penetrance"
    explanation: >-
      Establishes the genetic landscape: over 250 BEST1 pathogenic variants
      underlie the bestrophinopathies, with variable expressivity and incomplete
      penetrance characterizing the dominant forms.
  - reference: DOI:10.1002/mgg3.2095
    reference_title: "BEST1 novel mutation causes Bestrophinopathies in six families with distinct phenotypic diversity"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 9 variants on the BEST1 gene were identified, containing 7 missense variants, 1 nonsense variant, and 1 frameshift variant"
    explanation: >-
      Family-based genetic study of bestrophinopathies demonstrates the variant
      type distribution: predominantly missense, with minority
      frameshift/nonsense variants.
  - reference: DOI:10.4103/sjopt.sjopt_175_23
    reference_title: "Gene therapy in bestrophinopathies: Insights from preclinical studies in preparation for clinical trials"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "most BEST1 pathogenic variants have been shown to cause either loss of function (LOF) of the protein or a dominant-negative (DN) effect, with a smaller subset causing a toxic gain of function (GOF)"
    explanation: >-
      Categorizes BEST1 variant molecular mechanisms with important therapeutic
      implications: GOF variants require combined gene silencing + augmentation
      versus augmentation alone for LOF/DN.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    BVMD follows autosomal dominant inheritance with incomplete penetrance and
    marked variable expressivity. Asymptomatic carriers with pathogenic BEST1
    variants may show only reduced EOG without visible macular lesions.
    Intrafamilial phenotypic diversity is pronounced, with some heterozygous
    carriers showing no visible fundus changes.
  evidence:
  - reference: DOI:10.1002/mgg3.2095
    reference_title: "BEST1 novel mutation causes Bestrophinopathies in six families with distinct phenotypic diversity"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients carrying a pathogenic heterozygous variant of BEST1 to develop obvious intrafamilial phenotypic diversity"
    explanation: >-
      Family-based clinical genetic study demonstrates marked intrafamilial
      phenotypic diversity characteristic of dominant BEST1 disease with variable
      expressivity.
  - reference: DOI:10.1177/2515841421997191
    reference_title: "Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "over 250 individual pathological mutations have been identified in the BEST1 gene, with many reported to have various clinical expressivity and incomplete penetrance"
    explanation: >-
      Documents incomplete penetrance and variable clinical expressivity as
      characteristic features of dominant BEST1 inheritance.
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BVMD, AVMD, and ADVIRC are inherited in an autosomal dominant (AD) manner."
    explanation: >-
      GeneReviews explicitly confirms autosomal dominant inheritance as the mode
      for all three dominant BEST1 bestrophinopathy phenotypes.
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Each child of an affected individual has a 50% chance of inheriting the BEST1 pathogenic variant."
    explanation: >-
      GeneReviews documents the foundational AD transmission risk: each child of
      an affected parent has a 50% chance of inheriting the causative BEST1 variant,
      forming the basis of genetic counseling for this disorder.
treatments:
- name: Anti-VEGF Therapy for Choroidal Neovascularization
  description: >-
    Intravitreal anti-VEGF agents (e.g., bevacizumab, ranibizumab) are the
    current standard of care for exudative choroidal neovascularization
    complicating late-stage BVMD. No approved disease-modifying therapy exists
    for the underlying bestrophinopathy.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: angiogenesis inhibitor (anti-VEGF)
      term:
        id: NCIT:C1742
        label: Angiogenesis Inhibitor
  target_phenotypes:
  - preferred_term: Choroidal neovascularization
    term:
      id: HP:0011506
      label: Choroidal neovascularization
  evidence:
  - reference: DOI:10.1177/2515841421997191
    reference_title: "Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "no current clinical treatments available for patients with bestrophinopathies"
    explanation: >-
      Confirms that no approved disease-modifying treatment exists for
      bestrophinopathies; anti-VEGF for CNV is the only currently available
      targeted intervention.
  - reference: PMID:36281445
    reference_title: "Temporary Vitelliform Regression After Intravitreal Ranibizumab Injection for Macular Neovascularization Complicating Best Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "suggest a favorable long-term prognosis for intravitreal anti-VEGF injections in eyes with BVMD presenting with early complicating MNVs"
    explanation: >-
      Case report with 2-year follow-up documents a favorable response to
      intravitreal anti-VEGF (ranibizumab) for macular neovascularization
      complicating BVMD, supporting anti-VEGF as standard of care for the
      exudative/neovascular complication.
- name: OPGx-BEST1 Gene Augmentation Therapy (BIRD-1 Trial)
  description: >-
    OPGx-BEST1 (Opus Genetics) is a recombinant AAV vector delivering a
    codon-optimized full-length human BEST1 cDNA under an RPE-specific VMD2
    promoter, administered by subretinal injection. The Phase 1b/2a BIRD-1 trial
    (NCT07185256) opened for enrollment in 2025, exploring two doses (1.5E9 and
    4.5E9 vg/eye) with 5-year follow-up. Both LOF and DN mutations are potentially
    amenable to gene augmentation alone; GOF variants would require concurrent
    gene silencing.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_phenotypes:
  - preferred_term: Vitelliform macular lesion
    term:
      id: HP:0007677
      label: Vitelliform-like macular lesions
  evidence:
  - reference: clinicaltrials:NCT07185256
    reference_title: "A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients With Either Autosomal-Dominant BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD]) or Autosomal-Recessive Bestrophinopathy (ARB)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the treatment eye), for 5 years post-injection, in participants with BVMD or ARB"
    explanation: >-
      The first interventional gene therapy trial for bestrophinopathies is
      actively recruiting; OPGx-BEST1 subretinal gene delivery targets both
      BVMD (dominant) and ARB (recessive) patients.
  - reference: DOI:10.3390/ijms26199421
    reference_title: "Gene Therapy Strategies for the Treatment of Bestrophinopathies"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "gene augmentation may be effective for a subset of bestrophinopathies, others require allele-specific silencing or correction of the disease-causing variant"
    explanation: >-
      Establishes that gene augmentation (the OPGx-BEST1 approach) is
      appropriate for LOF/DN variants but that GOF variants require additional
      silencing strategies, informing patient eligibility and future trial design.
  - reference: DOI:10.4103/sjopt.sjopt_175_23
    reference_title: "Gene therapy in bestrophinopathies: Insights from preclinical studies in preparation for clinical trials"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "individuals harboring GOF variants would require a combination of gene silencing and gene augmentation, which has been shown to be effective in RPE cells derived from patients with Best disease"
    explanation: >-
      Demonstrates proof-of-concept for combined silencing + augmentation for
      GOF BEST1 variants in iPSC-RPE, supporting the therapeutic rationale for
      BEST1 gene therapy.
- name: Annual Ophthalmologic Surveillance
  description: >-
    Annual ophthalmologic examination including best-corrected visual acuity,
    visual fields, and spectral-domain OCT to monitor fundus lesion progression
    and detect the development of choroidal neovascularization. In children with
    BVMD, annual ophthalmologic examinations also help prevent amblyopia development.
  treatment_term:
    preferred_term: eye examination
    term:
      id: MAXO:0001155
      label: eye examination
  target_phenotypes:
  - preferred_term: Choroidal neovascularization
    term:
      id: HP:0011506
      label: Choroidal neovascularization
  - preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  evidence:
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Annual ophthalmologic examination (including best corrected visual acuity, visual fields, and spectral domain optical coherence tomography) to monitor progression of fundus lesions and to evaluate for coincidental development of CNV; in childhood, perform annual ophthalmologic examinations to help prevent the development of amblyopia."
    explanation: >-
      GeneReviews recommends annual ophthalmologic surveillance including BCVA,
      visual fields, and SD-OCT as standard of care for bestrophinopathies,
      specifically to monitor disease progression and detect CNV.
- name: Genetic Counseling
  description: >-
    Genetic counseling is recommended for all affected individuals and their
    families, particularly given the autosomal dominant inheritance with
    incomplete penetrance and marked variable expressivity, and the availability
    of cascade genetic testing for at-risk family members.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: DOI:10.1177/2515841421997191
    reference_title: "Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "over 250 individual pathological mutations have been identified in the BEST1 gene, with many reported to have various clinical expressivity and incomplete penetrance"
    explanation: >-
      The broad genetic heterogeneity and variable penetrance/expressivity of
      dominant BEST1 disease make genetic counseling essential for accurate
      risk assessment and family planning guidance.
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once the BEST1 pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for a bestrophinopathy are possible."
    explanation: >-
      GeneReviews confirms that once a causative BEST1 variant is identified,
      prenatal diagnostic testing and preimplantation genetic testing are
      available options, which should be communicated during genetic counseling.
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evaluation of relatives at risk: It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from prompt ophthalmologic evaluation and routine follow up."
    explanation: >-
      GeneReviews recommends cascade genetic testing for at-risk relatives,
      because asymptomatic carriers may have subclinical RPE dysfunction
      detectable only by EOG or molecular testing.
epidemiology:
- name: Prevalence
  description: >-
    BVMD is among the more prevalent inherited macular dystrophies. Over 250
    pathogenic BEST1 variants have been catalogued worldwide, with phenotypic
    and variant frequency differences across populations.
  evidence:
  - reference: DOI:10.1177/2515841421997191
    reference_title: "Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bestrophinopathies are a group of clinically distinct inherited retinal dystrophies that typically affect the macular region, an area synonymous with central high acuity vision."
    explanation: >-
      Characterizes bestrophinopathies as an important class of inherited macular
      dystrophies affecting the central high-acuity retina.
progression:
- phase: Five-stage macular evolution (BVMD)
  notes: >-
    BVMD evolves through five classical stages: (1) Previtelliform — subtle
    RPE irregularity or normal fundus, relatively normal VA; (2) Vitelliform —
    classic dome-shaped "egg-yolk" subfoveal yellow lesion, often preserved VA;
    (3) Pseudohypopyon — vitelliform material layers inferiorly within the lesion,
    variable VA; (4) Vitelliruptive/"scrambled-egg" — fragmented lesion with
    ONL thinning and EZ disruption, declining VA; (5) Atrophic/fibroatrophic —
    macular atrophy or fibrosis with severe and often irreversible central vision
    loss. Visual acuity is characteristically preserved longer than structural
    appearance suggests, consistent with the slow disease progression.
  evidence:
  - reference: DOI:10.1111/aos.14958
    reference_title: "Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "categorization of 52 eyes as Best vitelliform macular dystrophy (BVMD) with stages 1 to 5"
    explanation: >-
      Clinical cohort of 62 bestrophinopathy eyes demonstrates the five-stage
      BVMD classification system, including stage 5 (atrophic/cicatricial).
  - reference: DOI:10.1177/11206721231166434
    reference_title: "Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "effective diagnosis, staging, and clinical management of BVMD will likely require a deep understanding of the multimodal imaging features of this disease"
    explanation: >-
      Multimodal imaging review establishes that BVMD staging requires
      integration of fundoscopy, OCT, FAF, and OCT-A data across disease stages.
  - reference: PMID:20301346
    reference_title: "Bestrophinopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Onset is usually in the first decade (except AVMD in which onset is age 30 to 50 years). Slow visual deterioration is the usual course."
    explanation: >-
      GeneReviews anchors onset (first decade for BVMD) and the characteristically
      slow clinical trajectory, underpinning the five-stage natural history model
      and the long therapeutic window for future interventions.
animal_models:
- species: Dog
  genotype: Best1 loss-of-function (CMR1/2/3 — canine multifocal retinopathy)
  description: >-
    Canine multifocal retinopathy (CMR) is a naturally occurring bestrophinopathy
    in multiple dog breeds caused by autosomal-recessive BEST1 mutations
    (cmr1: p.Arg25Ter in Great Pyrenees/mastiff; cmr2: p.Gly161Asp in Coton de
    Tulear; cmr3: two variants in Swedish Lapponian Herder). Although CMR
    inheritance is recessive (unlike human BVMD), it recapitulates key features:
    multifocal retinal microdetachments, lipofuscin accumulation, and RPE
    microvilli loss. Subretinal AAV2-mediated BEST1 gene augmentation therapy in
    CMR dogs reversed both clinically detectable subretinal lesions and the diffuse
    RPE-photoreceptor microdetachment and corrected the RPE-photoreceptor interface
    across three canine BEST1 genotypes, providing the key preclinical
    proof-of-concept for the OPGx-BEST1 gene therapy approach.
  evidence:
  - reference: PMID:29507198
    reference_title: "BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Subretinal BEST1 gene augmentation therapy using adeno-associated virus 2 reversed not only clinically detectable subretinal lesions but also the diffuse microdetachments"
    explanation: >-
      In the canine BEST1 (CMR) model, subretinal AAV2-BEST1 gene augmentation
      reversed both clinically visible subretinal lesions and the diffuse
      RPE-photoreceptor microdetachment, the pivotal preclinical proof-of-concept
      underpinning the OPGx-BEST1 clinical gene therapy program.
  - reference: DOI:10.3390/cells9040882
    reference_title: "Large Animal Models of Inherited Retinal Degenerations: A Review"
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Studies utilizing large animal models of inherited retinal degeneration (IRD) have proven important in not only the development of translational therapeutic approaches, but also in improving our understanding of disease mechanisms"
    explanation: >-
      Large animal model review establishes the critical translational role of
      canine IRD models for inherited retinal disease gene therapy development,
      including for bestrophinopathy.
  - reference: DOI:10.1007/s00335-024-10091-y
    reference_title: "Canine models of inherited retinal diseases: from neglect to well-recognized translational value"
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Large animal models of inherited retinal diseases, particularly dogs, have been extensively used over the past decades to study disease natural history and evaluate therapeutic interventions"
    explanation: >-
      Canine IRD model review highlights the central role of dog models in
      bestrophinopathy translational research, from natural history to gene
      therapy preclinical evaluation.
- species: Mouse
  genotype: Best1 W93C knock-in and Best1 knockout
  description: >-
    Best1 W93C knock-in mice (heterozygous and homozygous) exhibit an altered EOG
    light-peak luminance response reminiscent of BVMD patients, together with
    fluid- and debris-filled retinal detachments and enhanced RPE lipofuscin
    accumulation, yet retain normal chloride conductances — indicating that the
    dominant disease is not simply loss of bestrophin-1 chloride-channel function.
    The knock-in phenotype is distinct from that of Best1 knockout mice (with
    respect to lipofuscin accumulation and ATP-stimulated calcium responses), and
    the W93C knock-in is regarded as a valid model of BVMD. Overall, mouse models
    incompletely recapitulate human BVMD, limiting their translational utility
    relative to canine models and iPSC-RPE systems.
  evidence:
  - reference: PMID:20053664
    reference_title: "Suppression of Ca2+ signaling in a mouse model of Best disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Both Best1(+/W93C)and Best1(W93C/W93C) mice had normal ERG a- and b-waves, but exhibited an altered LP luminance response reminiscent of that observed in BVMD patients"
    explanation: >-
      Knock-in mouse study shows the dominant BVMD-causing W93C variant produces
      the hallmark altered EOG light-peak (LP) response with normal ERG, modeling
      the human electrophysiological phenotype of BVMD.
  - reference: PMID:20053664
    reference_title: "Suppression of Ca2+ signaling in a mouse model of Best disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "RPE cells from Best1(W93C) mice exhibited normal Cl(-) conductances"
    explanation: >-
      Despite reproducing the disease phenotype, W93C knock-in RPE retains normal
      chloride conductance, showing that dominant BVMD pathology is not simply
      loss of bestrophin-1 chloride-channel function.
references:
- reference: PMID:20301346
  title: "Bestrophinopathies."
  tags:
  - GeneReviews
- reference: DOI:10.1177/2515841421997191
  title: "Bestrophinopathies: perspectives on clinical disease, Bestrophin-1 function and developing therapies"
- reference: DOI:10.4103/sjopt.sjopt_175_23
  title: "Gene therapy in bestrophinopathies: Insights from preclinical studies in preparation for clinical trials"
- reference: DOI:10.3390/ijms26199421
  title: "Gene Therapy Strategies for the Treatment of Bestrophinopathies"
- reference: DOI:10.1177/11206721231166434
  title: "Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights"
- reference: DOI:10.3390/ijms23137432
  title: "Impaired Bestrophin Channel Activity in an iPSC-RPE Model of Best Vitelliform Macular Dystrophy (BVMD) from an Early Onset Patient Carrying the P77S Dominant Mutation"
- reference: DOI:10.1111/aos.14958
  title: "Disease expression caused by different variants in the BEST1 gene: genotype and phenotype findings in bestrophinopathies"
- reference: DOI:10.1007/s10633-026-10093-y
  title: "Review of the clinical electrooculogram - Part 2: the bestrophinopathies and modified protocols"
- reference: DOI:10.1002/mgg3.2095
  title: "BEST1 novel mutation causes Bestrophinopathies in six families with distinct phenotypic diversity"
- reference: DOI:10.3390/cells9040882
  title: "Large Animal Models of Inherited Retinal Degenerations: A Review"
- reference: DOI:10.1007/s00335-024-10091-y
  title: "Canine models of inherited retinal diseases: from neglect to well-recognized translational value"
- reference: PMID:20053664
  title: "Suppression of Ca2+ signaling in a mouse model of Best disease."
- reference: PMID:29507198
  title: "BEST1 gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure."
- reference: PMID:36281445
  title: "Temporary Vitelliform Regression After Intravitreal Ranibizumab Injection for Macular Neovascularization Complicating Best Disease."
- reference: clinicaltrials:NCT07185256
  title: "A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients With Either Autosomal-Dominant BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD]) or Autosomal-Recessive Bestrophinopathy (ARB)"

📚